LCZ696 is effective in treating patients with heart failure:based on PARADIGM-HF data
10.11958/j.issn.0253-9896.2015.08.002
- VernacularTitle:LCZ696开启射血分数减低心力衰竭患者治疗的新时代：来自PARADIGM-HF的证据
- Author:
Yanmin XU
;
Dongxin WANG
;
Zhanqian CUI
;
Xingmei GUO
- Publication Type:Journal Article
- Keywords:
heart failure;
LCZ696;
neuroendocrine;
PARADIGM-HF
- From:
Tianjin Medical Journal
2015;(8):837-839,840
- CountryChina
- Language:Chinese
-
Abstract:
Heart failure (HF) is a complex clinical syndrome, which is caused by cardiac structural abnormalities and dysfunction. It can lead to ventricular filling and impaired ejection capacity with high incidence and mortality . The constant activation of the rennin-angiotensin-aldosterone system (RAAS) plays an important role in the development of heart failure. Angiotensin angiotensin converting enzyme inhibitor (ACEI), angiotensin angiotensin receptor antagonist (ARB) and aldoste?rone receptor antagonist (MRA) had been confirmed to be with good therapeutic effects therefore played important roles in heart failure treatment strategy shown by large scale clinical trials. The first PARADIM-HF data published by European So?ciety of Cardiology in annual meeting on August 30, 2014 showed that LCZ696 can reduce cardiovascular mortality risk of HF patient by 20%when combining with beta blockers and MRA . It also reduced the number of hospitalizations of patients with chronic heart failure (CHF) by 21%. LCZ696, using its unique dual phase mode verified that the regulation of neuroen?docrine is the modern concept for the treatment of heart failure. LCZ696 lead to innovation and shed new light in traditional drug treatment for heart failure.
